1. Banerjee S. N. T. G. Emori D. H. Culver R. P. Gaynes W. R. Jones T. Horan et al. 1991. Secular trends in nosocomial primary blood stream infections in the United States 1980-1989. Am. J. Med. 91(Suppl. 3B):86S-89S.
2. Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography;Fischman A. J.;Antimicrob. Agents Chemother.,1993
3. Klepser M. E. E. J. Wolfe and M. A. Pfaller. 1996. Characterization of the fungicidal dynamics of fluconazole (FLU) and amphotericin B (AB) against Cryptococcus neoformans via kill-curve methodologies abstr. 77 p. 50. In Program and Abstracts of the 34th Annual Meeting of the Infectious Diseases Society of America.
4. .Klepser M. E. E. J. Wolfe R. N. Jones C. H. Nightingale and M. A. Pfaller. 1996. Characterization of the fungicidal dynamics of fluconazole (FLU) and amphotericin B (AB) against C. albicans via kill-curve methodologies abstr. E51 p. 90. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology Washington D.C.
5. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard M27-T. National Committee for Clinical Laboratory Standards Villanova Pa.